Recent Updates
Recently added Catalysts
XTNT Positive Sentiment

Xtant Medical Announces Record Third Quarter Revenue of $25 Million

Thursday, November 9, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Xtant Medical Holdings, Inc. reported a record revenue of $25 million for the third quarter of 2023. The company has also raised its annual revenue guidance to between $88 million and $91 million. This positive financial performance highlights the company's growth in surgical solutions for spinal disorders.
Price reaction · baseline $1.21 (2023-11-08 close) · hit pre-market · clean, no other XTNT news in the window
day 0 close
-2.5%

Market Sentiment Analysis

POSITIVE FACTORS

  • Record third quarter revenue of $25 million reported.
  • Raised annual revenue guidance to $88 million - $91 million.
  • Strong performance in surgical solutions for spinal disorders.

Full Press Release Details

Raises 2023 Annual Revenue Guidance to $88 Million – $91 Million BELGRADE, Mont. , Nov. 09, 2023 (GLOBE NEWSWIRE) — Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial

Frequently Asked Questions

What was Xtant Medical's Q3 revenue?

Xtant Medical reported a record revenue of $25 million for the third quarter.

What is the new revenue guidance for 2023?

The company raised its annual revenue guidance to $88 million - $91 million.

What does Xtant Medical focus on?

Xtant Medical focuses on surgical solutions for the treatment of spinal disorders.

ShareAdd on Google
Tags: XTNT Viatris Investor Conferences Healthcare Xtant Medical revenue guidance spinal disorders financial report
Last updated: Nov 9, 2023

Biotech snapshot

Cash runway
$10M liquidity · $2M/mo burn
~4 mo
High dilution risk